CLGN earnings: next report 2026-08-20, real EPS beat/miss history, analyst consensus Buy, P/E -0.31. Updated 2026-07-23.
CollPlant Biotechnologies (CLGN) Research Hub
CollPlant Biotechnologies (CLGN) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.5 USD (+2.64%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.31, market cap 0.00B. This hub links to the full technical, earnings and options research available for CLGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 3.5 USD (+2.64%) |
| 52-week range | 2.64 USD – 4.3 USD |
| Trend regime | Range |
| 14-day RSI | 52.1 (Neutral) |
| Trailing P/E | -0.31 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-20 |
Available research for CLGN
Covered Call on CLGN: how it works, illustrative setup around the real 3.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CLGN: how it works, illustrative setup around the real 3.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CLGN: how it works, illustrative setup around the real 3.5 USD price, max profit/loss, breakeven and when to use it. Educational.
CLGN technical analysis: range, last 3.5 USD, RSI 52.1, 52w range 2.64 USD–4.3 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CLGN in?
CollPlant Biotechnologies (CLGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is CLGN in an uptrend or downtrend?
As of 2026-09-11, CLGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CLGN's trailing P/E ratio?
CLGN's trailing P/E is -0.31, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does CLGN next report earnings?
CLGN is next scheduled to report earnings on 2026-08-20, with a consensus EPS estimate of -0.2448 USD.